Researchers design gene therapy that can effectively target glioblastoma
In a first-in-human phase 1 trial in 41 patients with recurrent glioblastoma, an oncolytic virus treatment designed by Brigham researchers extended survival, especially among those with pre-existing viral antibodies Therapy turns ‘immune desert’ into inflammatory cancer-fighting zone Study demonstrated the safety and preliminary efficacy of a novel gene therapy for glioblastoma Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, ...
Read the release















